Popular terms

Vasomotor topics
Selective Estrogen Receptor Modulators
Estrogen Receptor Modulators
Estrogen Receptor
Hormone Therapy
Calcitonin
Symptomatic
Azelastine
Memory Loss
Antagonist
Tension Headache
Antibodies
Cluster Headache
Therapeutical
Nutraceutical
Hot Flashes

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Vasomotor patents



      

This page is updated frequently with new Vasomotor-related patent applications.




Date/App# patent app List of recent Vasomotor-related patents
06/23/16
20160175586 
 Epidural stimulation for facilitation of locomotion, posture, voluntary movement, and recovery of autonomic, sexual, vasomotor, and cognitive function after neurological injury patent thumbnailEpidural stimulation for facilitation of locomotion, posture, voluntary movement, and recovery of autonomic, sexual, vasomotor, and cognitive function after neurological injury
Methods are described comprising: administering to a mammal with a paralysis an electrical enabling motor control stimulation to at a sub-threshold location, wherein the electrical enabling motor control stimulation provides spontaneous voluntary movement of at least one body part.. .

06/16/16
20160168244 
 Antagonist antibodies directed against calcitonin gene-related peptide and methods using same patent thumbnailAntagonist antibodies directed against calcitonin gene-related peptide and methods using same
The invention features methods for preventing or treating cgrp associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-cgrp antagonist antibody. Antagonist antibody g1 and antibodies derived from g1 directed to cgrp are also described..
Labrys Biologics, Inc.


03/24/16
20160082264 
 Implantable device including a stimulation lead for bioimpedance measurement patent thumbnailImplantable device including a stimulation lead for bioimpedance measurement
An implantable device includes a lead, for example for neurostimulation of the vagus nerve. The lead includes a series of stimulation electrodes and a series of external electrodes for bioimpedance measurements on blood flow located in the same region, for example on the carotid artery.
Sorin Crm Sas


02/04/16
20160030748 
 High density epidural stimulation for facilitation of locomotion, posture, voluntary movement, and recovery of autonomic, sexual, vasomotor, and cognitive function after neurological injury patent thumbnailHigh density epidural stimulation for facilitation of locomotion, posture, voluntary movement, and recovery of autonomic, sexual, vasomotor, and cognitive function after neurological injury
Methods of enabling locomotor control, postural control, voluntary control of body movements (e.g., in non-weight bearing conditions), and/or autonomic functions in a human subject having spinal cord injury, brain injury, or neurological neuromotor disease are described.. .
California Institute Of Technology


12/17/15
20150361173 
 Antagonist antibodies directed against calcitonin gene-related peptide and methods using same patent thumbnailAntagonist antibodies directed against calcitonin gene-related peptide and methods using same
The invention features methods for preventing or treating cgrp associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-cgrp antagonist antibody. Antagonist antibody g1 and antibodies derived from g1 directed to cgrp are also described..
Labrys Biologics, Inc.


12/17/15
20150361172 
 Antagonist antibodies directed against calcitonin gene-related peptide and methods using same patent thumbnailAntagonist antibodies directed against calcitonin gene-related peptide and methods using same
The invention features methods for preventing or treating cgrp associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-cgrp antagonist antibody. Antagonist antibody g1 and antibodies derived from g1 directed to cgrp are also described..
Labrys Biologics, Inc.


12/17/15
20150361171 
 Antagonist antibodies directed against calcitonin gene-related peptide and methods using same patent thumbnailAntagonist antibodies directed against calcitonin gene-related peptide and methods using same
The invention features methods for preventing or treating cgrp associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-cgrp antagonist antibody. Antagonist antibody g1 and antibodies derived from g1 directed to cgrp are also described..
Labrys Biologics, Inc.


11/12/15
20150322142 
 Antagonist antibodies directed against calcitonin gene-related peptide and methods using same patent thumbnailAntagonist antibodies directed against calcitonin gene-related peptide and methods using same
The invention features methods for preventing or treating cgrp associated disorders such as vasomotor symptoms and/or headaches (e.g., migraine, cluster headache, and tension headache) by administering an anti-cgrp antagonist antibody. Compositions for use in the disclosed methods are also provided.
Labrys Biologics, Inc.


10/15/15
20150291690 
 Antagonist antibodies directed against calcitonin gene-related peptide and methods using same patent thumbnailAntagonist antibodies directed against calcitonin gene-related peptide and methods using same
The invention features methods for preventing or treating cgrp associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-cgrp antagonist antibody. Antagonist antibody g1 and antibodies derived from g1 directed to cgrp are also described..

10/01/15
20150272927 
 Methods and compositions for treating vasomotor symptoms patent thumbnailMethods and compositions for treating vasomotor symptoms
The present disclosure is generally directed to compositions and methods for treating or limiting development of vasomotor symptoms in a subject.. .
University Of Washington Through Its Center For Commercialization


09/24/15
20150266948 

Antagonist antibodies directed against calcitonin gene-related peptide and methods using same


The invention features methods for preventing or treating cgrp associated disorders such as vasomotor symptoms and/or headaches (e.g., migraine, cluster headache, and tension headache) by administering an anti-cgrp antagonist antibody. Compositions for use in the disclosed methods are also provided.
Labrys Biologics, Inc.


09/10/15
20150250783 

Treatment of vasomotor symptoms


The invention relates to a method for the treatment of vasomotor symptoms comprising the administration of a therapeutically effective amount of flibanserin.. .
Sprout Pharmaceuticals Inc.


06/18/15
20150164924 

Di-isopropyl-phosphinoyl-alkanes as topical agents for the treatment of sensory discomfort


The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to certain di-isopropyl-phosphinoyl-alkanes as described herein, dipa-1-5, dipa-1-6, dipa-1-7, dipa-1-8, and dipa-1-9, collectively referred to herein as “dipa compounds”, that are useful, for example, in the treatment of disorders (e.g., diseases) including: sensory discomfort (e.g., caused by irritation, itch, or pain); a skin dysesthesia; dermatitis; ocular pain and discomfort; heat discomfort; heat stress; flushing and/or night sweats (vasomotor symptoms); post-operative hypothermia; post-anaesthetic shivering; fatigue; tiredness; depression; cognitive dysfunction; and to enhance cognitive function.

06/11/15
20150157683 

Anti-diabetic nutraceutical composition from palm leaf extract


A comestible composition with anti-diabetic property which is effective in lowering the blood glucose and help reduce oxidative stress in diabetics and have anti-diabetic properties that protect against diabetic complications, retarding diabetes related organ degeneration and effective to hinder or prevent ailments or conditions resulting from, or exacerbated by, a chronic increase in blood sugar including: tissue degeneration, cardiovascular disease, kidney degeneration, loss of cognitive function, weight loss, visual impairment, and vasomotor symptoms which contains extract from palm leaf. .
Universiti Putra Malaysia


04/30/15
20150119453 

Compositions and methods for the treatment of depression


The invention relates to the compounds of formula i or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula i, and methods for treating or preventing depression may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection.

02/19/15
20150050267 

Antagonist antibodies directed against calcitonin gene-related peptide and methods using same


The invention features methods for preventing or treating cgrp associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-cgrp antagonist antibody. Antagonist antibody g1 and antibodies derived from g1 directed to cgrp are also described..
Labrys Biologics, Inc.


01/29/15
20150031700 

Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists


The present invention relates to a method of treating, reducing, inhibiting, preventing and/or reversing cutaneous facial flushing caused by abnormal, endogenously-induced vasomotor instability associated with, but not limited to acne rosacea, menopause-associated hot flashes, hot flashes resulting from orchiectomy or ingestion of substances capable of inducing a cutaneous facial flushing reaction (e.g.: alcohol, chocolate, spices) by topical dermatological application of an effective dose of a composition comprising at least one α2 adrenergic receptor agonist (such as a (2-imidazolin-2-ylamino) quinoxaline derivative such as brimonidine tartrate)and a suitable carrier.. .
Galderma Laboratories Inc.


10/23/14
20140316484 

Non invasive neuromodulation device for enabling recovery of motor, sensory, autonomic, sexual, vasomotor and cognitive function


In one example embodiment, a neuromodulation system for inducing locomotor activity in a mammal, in cooperation with a signal generator and an electrode, delivers a signal with an overlapping high frequency pulse to a mammal. .

09/18/14
20140278285 

Method for quantitative diagnosis of cerebrovascular, neurovascular and neurodegenerative diseases via computation of a co2 vasomotor reactivity index based on a nonlinear predictive model


The present invention relates generally to a method for computer-aided quantitative diagnosis of cerebrovascular and neurodegenerative diseases (such as alzheimer's, vascular dementia, mild cognitive impairment, transient ischemia, stroke etc.) via a vasomotor reactivity index (vmri) which is computed on the basis of a computational model of the dynamic nonlinear inter-relationships between beat-to-beat time-series measurements of cerebral blood flow velocity, arterial blood pressure and end-tidal co2. This model is obtained by means of a method pioneered by the inventors and may incorporate additional physiological measurements from human subjects.

07/03/14
20140187941 

Evaluating arterial pressure, vasomotor activity and their response to diagnostic tests


Method and system for evaluating arterial pressure waves, vascular properties, as well as for diagnostic, physiological and pharmacological testing using various combinations of the following data acquisition and processing steps (some of the steps are optional): 1. Perturbing arterial pressure from its steady state.

06/12/14
20140163640 

High density epidural stimulation for facilitation of locomotion, posture, voluntary movement, and recovery of autonomic, sexual, vasomotor, and cognitive function after neurological injury


Methods of enabling locomotor control, postural control, voluntary control of body movements (e.g., in non-weight bearing conditions), and/or autonomic functions in a human subject having spinal cord injury, brain injury, or neurological neuromotor disease. In certain embodiments, the methods involve stimulating the spinal cord of the subject using an epidurally placed electrode array, subjecting the subject to physical training thereby generating proprioceptive and/or supraspinal signals, and optionally administering pharmacological agents to the subject.

06/12/14
20140158117 

Compositions comprising azelastine and methods of use thereof


The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize or mask the unpleasant bitter taste associated with post-nasal drip, of the compositions, into the oral cavity, upon intranasal or ocular administration of the compositions.

05/29/14
20140147438 

Methods of treating vasomotor symptoms using antibodies


The invention features methods for preventing or treating cgrp associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-cgrp antagonist antibody. Antagonist antibody g1 and antibodies derived from g1 directed to cgrp are also described..

01/02/14
20140005203 

Treatment of vasomotor symptoms


The invention relates to a method for the treatment of vasomotor symptoms comprising the administration of a therpeutically effective amount of flibanserin.. .

08/22/13
20130216535 

Antagonist antibodies directed against calcitonin gene-related peptide and methods using same


The invention features methods for preventing or treating cgrp associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-cgrp antagonist antibody. Antagonist antibody g1 and antibodies derived from g1 directed to cgrp are also described..

06/20/13
20130158121 

Methods for treating vasomotor symptoms using gaba analogs in a gastric retentive dosage form


Methods for treating vasomotor symptoms associated with menopause are described.. .

05/09/13
20130116242 

Method of treatment of hormone depletion induced vasomotor


The invention provides a method to effectively wean a woman from hormone therapy for treatment of vasomotor symptoms by reducing the dosage of the hormonal agent to zero, while a non-hormonal drug in an amount, which is therapeutically effective for treating vasomotor symptoms, is administered or initiated and continued for a limited period of a duration between 3 and 8 months.. .



Vasomotor topics: Selective Estrogen Receptor Modulators, Estrogen Receptor Modulators, Estrogen Receptor, Hormone Therapy, Calcitonin, Symptomatic, Azelastine, Memory Loss, Antagonist, Tension Headache, Antibodies, Cluster Headache, Therapeutical, Nutraceutical, Hot Flashes

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Vasomotor for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Vasomotor with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.2289

1266

1 - 1 - 28